You are here
GMSI Award 2015 – Introduction and Welcome
This lecture was given at the GMSI Award Event, 8th October 2015. The GMSI award was supported by Merck KGaA, Darmstadt, Germany.
Professor Bates is in the Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Professor Bates said that the GMSI [Grant for Multiple Sclerosis Innovation] was first awarded in 2013. Merck Serono provides research grants of up to 1 million Euros and thereby demonstrated its commitment to immunology in general and multiple sclerosis in particular. The projects are translational research, largely by academic researchers. An attempt is made to apply the following criteria. The main criterion is that the research should improve understanding of multiple sclerosis for the benefit of patients, their relatives and carers. It should provide some more knowledge of pathogenesis. It would be desirable to have evidence of predictive markers of treatment response and disease progress. Potential new treatments are desirable, as would be more information about the various subtypes of multiple sclerosis.
Professor Bates introduced Steven Hildemann, who is Professor at Freiburg University and the Global Chief Medical Officer of Merck Serono. Professor Hildemann had been interested in the GMSI since its inception. He would give an update and introduce the four current award winners, who would explain the topics they plan to study.
David Bates11/09/2015 - 10:41Professor Bates said that the GMSI [Grant for Multiple Sclerosis Innovation] was first awarded in 2013. Merck Serono provides research grants of up to 1 million Euros and thereby demonstrated its commitment to immunology...
Steven Hildemann11/09/2015 - 10:49Merck-Serono's pipeline focuses on difficult to treat diseases with a high unmet medical need, in the four areas of oncology, immuno-oncology, immunology and multiple sclerosis.
David Bates11/09/2015 - 11:00Professor Bates briefly summarised progress made by the recipients of the 2013 and 2014 grants.
Elga de Vries11/17/2015 - 13:31Microglia in MS might have two different phenotypes, according to Dr. de Fries. M1 were pro-inflammatory and neurodestructive and might also be deleterious to neuronal function; M2 were anti-inflammatory and neuro-protective.
Laura Airas11/17/2015 - 13:40In her speech, the award winner Dr. Airas, said that it had been very difficult to find treatments for progressive multiple sclerosis. One reason was that the pathology changes as the disease progresses.
GMSI Award 2015 – Driving microglia metabolism towards remyelination and restoration of brain damage in multiple sclerosis
Claudia Verderio11/17/2015 - 13:53According to Dr. Verderio, the new proposal stemmed from data on the biological activity of vesicles from microglia cells, on the proliferation, differentiation and myelination of oligodendrocyte precursor cells (OPCs).
Gabriele de Luca11/17/2015 - 14:03Dr. de Luca explains in his talk that multiple sclerosis was unsurpassed in its variability and clinical outcomes. One of the greatest determinants of disease and disability was entry into the progressive phase.